Subscribe To
BLUE / bluebird (BLUE) Posts Q4 Loss, Hit by Regulatory Pipeline Woes
BLUE News
By Reuters
October 30, 2023
Bluebird bio to sell sickle cell gene therapy FDA voucher for $103 million if approved
Bluebird bio said on Monday it has agreed to sell its priority review voucher for $103 million, if it gets the U.S. Food and Drug Administration's app more_horizontal
By PennyStocks
October 17, 2023
Best Penny Stocks To Buy Now? These 3 Are Moving Fast In October
Are you looking for the best penny stocks to buy now? Today might be your day more_horizontal
By The Motley Fool
September 20, 2023
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
CRISPR Therapeutics and Bluebird Bio each have potential growth catalysts coming in the next 12 months. CRISPR Therapeutics has a powerful ally and pl more_horizontal
By The Motley Fool
September 12, 2023
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
The consensus price target for Recursion Pharmaceuticals suggests the stock can soar 88% from recent prices. The average analyst estimates for bluebir more_horizontal
By The Motley Fool
August 29, 2023
Is Bluebird Bio a Bargain Buy in September?
Bluebird Bio is strapped for cash, and a lot of must-do spending is coming up. It will likely need to scale up its clinic footprint while also launchi more_horizontal
By The Motley Fool
August 24, 2023
1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street
Bluebird Bio has two approved gene-editing treatments, but they aren't generating much sales yet. The small-cap biotech company could earn another app more_horizontal
By InvestorPlace
August 23, 2023
7 Very Oversold Nasdaq Stocks to Buy Right Now
The Nasdaq has taken a rather large hit in recent weeks, sinking about 7.5% between July 18 and Aug 17. Two of the main reasons for the decline are w more_horizontal
By Zacks Investment Research
August 17, 2023
bluebird's (BLUE) Lovo-cel to Not Face Advisory Committee
bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory com more_horizontal